217 related articles for article (PubMed ID: 27911816)
21. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
22. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
23. Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
Wu H; Liu Q; Cai T; Chen YD; Wang ZF
Mol Med Rep; 2015 Oct; 12(4):5461-6. PubMed ID: 26239619
[TBL] [Abstract][Full Text] [Related]
24. Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs.
Díaz Bessone MI; Berardi DE; Campodónico PB; Todaro LB; Lothstein L; Bal de Kier Joffé ED; Urtreger AJ
Breast Cancer Res Treat; 2011 Apr; 126(3):577-87. PubMed ID: 20512658
[TBL] [Abstract][Full Text] [Related]
25. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.
Podolski-Renić A; Andelković T; Banković J; Tanić N; Ruždijić S; Pešić M
Biomed Pharmacother; 2011 Aug; 65(5):345-53. PubMed ID: 21775090
[TBL] [Abstract][Full Text] [Related]
26. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
[TBL] [Abstract][Full Text] [Related]
28. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.
Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC
J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901
[TBL] [Abstract][Full Text] [Related]
29. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
[TBL] [Abstract][Full Text] [Related]
32. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
33. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.
Mi J; Zhang X; Rabbani ZN; Liu Y; Reddy SK; Su Z; Salahuddin FK; Viles K; Giangrande PH; Dewhirst MW; Sullenger BA; Kontos CD; Clary BM
Mol Ther; 2008 Jan; 16(1):66-73. PubMed ID: 17912235
[TBL] [Abstract][Full Text] [Related]
34. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S
Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979
[TBL] [Abstract][Full Text] [Related]
35. Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.
MacDiarmid JA; Langova V; Bailey D; Pattison ST; Pattison SL; Christensen N; Armstrong LR; Brahmbhatt VN; Smolarczyk K; Harrison MT; Costa M; Mugridge NB; Sedliarou I; Grimes NA; Kiss DL; Stillman B; Hann CL; Gallia GL; Graham RM; Brahmbhatt H
PLoS One; 2016; 11(4):e0151832. PubMed ID: 27050167
[TBL] [Abstract][Full Text] [Related]
36. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells.
Ho WC; Dickson KM; Barker PA
Cancer Res; 2005 May; 65(10):4273-81. PubMed ID: 15899819
[TBL] [Abstract][Full Text] [Related]
37. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
38. NFκB inhibitors induce cell death in glioblastomas.
Zanotto-Filho A; Braganhol E; Schröder R; de Souza LH; Dalmolin RJ; Pasquali MA; Gelain DP; Battastini AM; Moreira JC
Biochem Pharmacol; 2011 Feb; 81(3):412-24. PubMed ID: 21040711
[TBL] [Abstract][Full Text] [Related]
39. TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells.
Cho HY; Lee SW
Cell Immunol; 2014; 289(1-2):27-35. PubMed ID: 24709011
[TBL] [Abstract][Full Text] [Related]
40. NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma.
Wang H; Pan JQ; Luo L; Ning XJ; Ye ZP; Yu Z; Li WS
Mol Cancer; 2015 Feb; 14():2. PubMed ID: 25971746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
